Everest Medicines begins production at its new $129M+ mRNA vaccine manufacturing facility in China
The China-based biotech Everest Medicines has opened the doors to a new manufacturing facility to produce mRNA-based vaccines.
Everest’s new facility, which is located just to the west of Shanghai in Jiashan, Zhejiang Province, is around 58,000 square meters, or an estimated 624,306 square feet, and had an investment of more than RMB 900 million ($129 million). The manufacturing facility plans to produce around 700 million doses of mRNA vaccine annually.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.